GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

In the video attached to this article we take a look at HIMS.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A weekly injection of diabetes medication could replace painful daily hormone shots for patients with a rare form of lipodystrophy.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...